-
Podium to Practice: Navigating the New Landscape in Relapsed/Refractory Multiple Myeloma – Clinical Impact of Recently Presented Data_Updates from the 2021 ASCO and EHA Annual Meetings_Cristina Gasparetto, MD_Maria-Victoria Mateos, MD, PhD #ASCO2021 #EHA
40:46
-
Expert Insights: New Targets, New Agents, New Combinations: Navigating the New Landscape in Relapsed/Refractory Multiple Myeloma_Noopur Raje, MD_Joseph Mikhael, MD, MEd, FRCPC, FACP #ASCO21
29:13
-
Virtual Challenging Case Clinic: Multiple Myeloma_Updates from ASCO and EHA_Jonathan Kaufman, MD
54:43
-
Clinical Experience With Newly Approved Therapies_Joseph Mikhael, MD, MEd, FRCPC, FACP #ASCO21
21:43
-
Choosing the Right Combination Therapy_Krina Patel, MD, MSc #ASCO21
19:41
-
How to Manage Novel AE Patients_Noopur Raje, MD, Joseph Mikhael, MD, MEd, FRCPC, FACP, Krina Patel, MD, MSc #ASCO21
28:34
-
Evolving Profile of a Patient with Relapsed/Refractory MM_Noopur Raje, MD #ASCO21
9:41
-
Panel Discussion and Q&A_Noopur Raje, MD, Joseph Mikhael, MD, MEd, FRCPC, FACP, Krina Patel, MD, MSc #ASCO21
19:30
-
Shaji Kumar, MD; Mayo Clinic Rochester, MN; 5Live; #ASCO2021
6:09
-
Robert Orlowski, MD, PhD; The University of Texas MD Anderson Cancer Center; 5Live; #ASCO2021
4:48
-
Ravi Vij, MD, MBA; Washington University School of Medicine; 5Live; #ASCO2021
3:55
- Next Page
ABOUT
Bio Ascend is an independent medical education company committed to supporting healthcare providers in their efforts to translate innovative science into clinical practice.
The Bio Ascend team has deep oncology and hematology expertise with a proven ability to distill complex scientific ideas into their essential components, as well as extensive experience in planning, executing, and assessing meaningful education for clinicians.
CONNECT
© Copyright 2021 Bio Ascend, a Vaniam Group company